Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metro-PD1: Nivolumab + Metronomic Chemotherapy in Pediatric Refractory/Relapsing Solid Tumors
NCT03585465Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- Mar 2019
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab in solid tumor, sponsored by Centre Oscar Lambret. Started Mar 2019; status: terminated.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03585465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585465.